3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
5
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
71
Lymphoma, Large B-Cell, Diffuse
51
Neoplasms
41
Lymphoma, Non-Hodgkin
41
Multiple Myeloma
40
Lymphoma
37
Recurrence
35
Lymphoma, Follicular
30
Carcinoma, Non-Small-Cell Lung
30
Leukemia, Lymphocytic, Chronic, B-Cell
29
Lymphoma, B-Cell
26
Triple Negative Breast Neoplasms
23
Leukemia, Myeloid, Acute
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Ovarian Neoplasms
17
Lymphoma, Mantle-Cell
17
Leukemia
15
Pancreatic Neoplasms
14
Neoplasm Metastasis
14
Squamous Cell Carcinoma of Head and Neck
12
Stomach Neoplasms
11
Melanoma
11
Colorectal Neoplasms
11
Lymphoma, B-Cell, Marginal Zone
10
Prostatic Neoplasms
9
Head and Neck Neoplasms
9
Lymphoma, T-Cell, Peripheral
8
Liposarcoma, Myxoid
8
Carcinoma, Renal Cell
8
Sarcoma
7
Interventions
Fluorouracil
21
Oxaliplatin
17
Leucovorin
17
Bevacizumab
17
Irinotecan
13
Panitumumab
12
Cetuximab
12
IFL protocol
9
Capecitabine
9
pembrolizumab
7
Radiotherapy
7
Pemetrexed
5
Gemcitabine
5
labetuzumab
3
conatumumab
3
Cisplatin
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
5,11-methenyltetrahydrohomofolate
3
130-nm albumin-bound paclitaxel
3
vatalanib
2
trametinib
2
spartalizumab
2
pegfilgrastim
2
ganitumab
2
encorafenib
2
dostarlimab
2
Ramucirumab
2
Paclitaxel
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Rectal Neoplasms
×
Cyclophosphamide
×
Clear all
NCT01507103
2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
124 enrolled
9 charts